Roche

Key Takeaways • The cobas Mass Spec solution enhances early detection of therapeutic responses in hormone therapy. • Automation and standardization reduce operational variability across laboratories. •...

Key TakeawaysLunsumio significantly extends progression-free survival in relapsed follicular lymphoma. The treatment maintains a favorable safety profile over four years of use. Patients...

Key TakeawaysFixed-duration therapies like Columvi and Lunsumio provide sustained remissions, enhancing long-term patient outcomes. Subcutaneous Lunsumio offers a practical alternative to intravenous treatments,...

Key TakeawaysPolivy's combination therapy could redefine first-line treatment standards. Long-term data supports broader clinical adoption and guideline updates. Future studies may investigate Polivy's...

Key TakeawaysColumvi plus GemOx demonstrated a statistically significant and clinically meaningful improvement in overall survival. The fixed-duration treatment offers a timely option post-diagnosis...

Roche has unveiled new findings from its Phase III SKYSCRAPER-01 study, marking a significant milestone in the development of innovative treatments. The comprehensive analysis...

Roche has finalized a definitive merger agreement to obtain Poseida Therapeutics, a San Diego-based biopharmaceutical company specializing in donor-derived CAR-T cell therapies. The acquisition,...

User-Usable Inferences - Polivy demonstrates potential in combination therapies for DLBCL, showing positive survival trends. - Lunsumio and Columvi offer long-lasting remission and manageable safety profiles. -...

Key TakeawaysEarly testing for PIK3CA mutations can identify patients who may benefit from Itovebi-based therapy. The Itovebi regimen offers a promising first-line treatment...

Key TakeawaysThe Elecsys Amyloid Plasma Panel shows high accuracy in ruling out Alzheimer's, reducing the need for invasive tests. A negative result from...

A recent groundbreaking study has highlighted significant advancements in treating diabetic macular edema (DME) for African American, Black, Hispanic, and Latino populations. Conducted by...

Roche has unveiled promising data from its RAINBOWFISH study, highlighting Evrysdi's efficacy and safety in treating spinal muscular atrophy (SMA) in infants. This groundbreaking...

Key TakeawaysRoche’s Evrysdi® (risdiplam) demonstrated that the majority of children with spinal muscular atrophy (SMA), treated pre-symptomatically before six weeks of age, were...

Key TakeawaysItovebi™ (inavolisib) gains FDA approval for treating PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, showing over double the progression-free survival compared to standard...

Key TakeawaysGazyva/Gazyvaro significantly improves complete renal response rates in lupus nephritis patients compared to standard therapy alone. Secondary endpoints show a successful reduction...